Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
20.03
+1.02 (5.37%)
May 13, 2025, 4:00 PM - Market closed

Enliven Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
May '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Market Capitalization
9831,099570---
Market Cap Growth
92.74%92.74%----
Enterprise Value
669808307---
Last Close Price
20.0322.5013.84---
PB Ratio
3.163.552.32---
P/TBV Ratio
3.173.552.32---
Debt / Equity Ratio
--0.000.010.000.00
Quick Ratio
19.7019.709.787.7819.1388.20
Current Ratio
19.9919.9910.288.0019.2488.35
Return on Equity (ROE)
-32.04%-32.04%-44.90%-41.90%-20.94%-
Return on Assets (ROA)
-21.87%-21.87%-28.94%-24.66%-12.67%-
Return on Capital (ROIC)
-23.50%-23.50%-32.14%-26.86%-13.08%-
Earnings Yield
-9.06%-8.10%-12.55%---
FCF Yield
-7.45%-6.66%-10.77%---
Buyback Yield / Dilution
-32.43%-32.43%-1037.74%60.02%-56.70%-
Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q